Itau Unibanco Holding S.A. Invests $29,000 in IQVIA Holdings Inc. (NYSE:IQV)

Itau Unibanco Holding S.A. bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 137 shares of the medical research company’s stock, valued at approximately $29,000.

Other institutional investors have also added to or reduced their stakes in the company. First Foundation Advisors increased its holdings in shares of IQVIA by 3.8% during the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after acquiring an additional 43 shares in the last quarter. Team Hewins LLC increased its stake in IQVIA by 5.0% during the 1st quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 46 shares in the last quarter. Invera Wealth Advisors LLC raised its holdings in IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after buying an additional 46 shares during the last quarter. Covestor Ltd lifted its stake in shares of IQVIA by 45.3% in the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after buying an additional 48 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund increased its position in shares of IQVIA by 0.3% during the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after acquiring an additional 48 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently weighed in on IQV. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and dropped their price target for the company from $266.00 to $242.00 in a research report on Wednesday, July 24th. Evercore ISI raised their target price on IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Argus upgraded IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Barclays increased their price target on IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a research report on Tuesday, July 23rd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a report on Monday, August 5th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $267.00.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.60% of the stock is currently owned by insiders.

IQVIA Stock Down 1.0 %

IQV opened at $242.12 on Monday. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The company’s 50-day moving average price is $240.60 and its two-hundred day moving average price is $233.94. The stock has a market cap of $44.14 billion, a price-to-earnings ratio of 33.08, a PEG ratio of 2.25 and a beta of 1.49. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. IQVIA’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.22 earnings per share. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.